Better safety and quality of life in patients with chronic hepatitis B than in patients with chronic hepatitis C when treated with peginterferon alfa-2a (40KD) (PEGASYS®) monotherapy

被引：0
|
作者：
Marcellin, P
Lau, G
Piratvisuth, T
Luo, KX
Bonino, F
Thongasawat, S
Cooksley, G
Hadziyannis, S
Chutaputti, A
Lu, ZM
Fried, M
Chow, WC
Yurdaydin, C
Berg, T
Pluck, N
机构：
[1] Hop Beaujon, Clichy, France
[2] Queen Mary Hosp, Hong Kong, Hong Kong, Peoples R China
[3] Songklanakarin Hosp, Songkhla, Thailand
[4] Nangfang Hosp, Guangzhou, Peoples R China
[5] IRCCS Osped Maggiore, Sci Direct, Milan, Italy
[6] Chiang Mai Univ, Chiang Mai 50000, Thailand
[7] Univ Queensland, Royal Brisbane Hosp, Herston, Qld, Australia
[8] H Dynant Hosp, Athens, Greece
[9] Pramongkutklao Hosp, Bangkok, Thailand
[10] Ruijin Hosp, Shanghai, Peoples R China
[11] Univ N Carolina, Chapel Hill, NC USA
[12] Singapore Gen Hosp, Singapore 0316, Singapore
[13] Ankara Univ, TR-06100 Ankara, Turkey
[14] Charite Humboldt Univ Berlin, Berlin, Germany
[15] Roche, Welwyn Garden City, England
来源：
HEPATOLOGY | 2004年 / 40卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：668A / 668A
页数：1
相关论文
共 50 条
  • [31] Asian patients with HBeAg-negative chronic hepatitis B respond well to peginterferon alfa-2a (40 KD) (PEGASYS®) treatment
    Jia, Ji-Dong
    Piratvisuth, Teerha
    Lau, George K. K.
    Luo, Kang-Xian
    Jin, Rui
    Lu, Zhi-Meng
    Marcellin, Patrick
    Popescu, Matei
    Button, Peter
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2006, 21 : A88 - A88
  • [32] ALT flares in patients with HBeAg-positive chronic hepatitis B and treated with either conventional interferon alfa-2a or peginterferon alfa-2a (40KD) (PEGASYS®) are not necessary for a significant response to therapy.
    Cooksley, WGE
    Lai, MY
    Piratvisuth, T
    Wang, YJ
    Mahachai, V
    Chao, YC
    Tanwandee, T
    Chutaputti, A
    Chang, WY
    Zahm, FE
    Pluck, N
    HEPATOLOGY, 2003, 38 (04) : 724A - 724A
  • [33] Peginterferon alfa-2a (40KD) plus ribavirin in chronic hepatitis C patients who failed previous interferon therapy
    Sherman, M.
    Yoshida, E. M.
    Deschenes, M.
    Krajden, M.
    Bain, V. G.
    Peltekian, K.
    Anderson, F.
    Kaita, K.
    Simonyi, S.
    Balshaw, R.
    Lee, S. S.
    GUT, 2006, 55 (11) : 1631 - 1638
  • [34] Efficacy of peginterferon alfa-2a (40KD) and ribavirin in patients with chronic hepatitis C in Germany -: A contribution to health care research
    Zehnter, E
    Mauss, S
    John, C
    Heyne, R
    Möller, B
    Bokemeyer, B
    Moog, G
    Alshuth, U
    Hüppe, D
    HEPATOLOGY, 2005, 42 (04) : 683A - 683A
  • [35] Treatment of patients with chronic hepatitis C and normal alanine aminotransferase levels with peginterferon alfa-2a (40 KD) (Pegasys®) and ribavirin.
    Zeuzem, S
    Diago-Madrid, M
    Shiffman, ML
    Reindollar, RW
    Pockros, PJ
    Gane, E
    Tran, A
    Farci, P
    Lamour, F
    HEPATOLOGY, 2002, 36 (04) : 583A - 583A
  • [36] Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin
    Ferenci, P
    Fried, MW
    Shiffman, ML
    Smith, CI
    Marinos, G
    Gonçales, FL
    Häussinger, D
    Diago, M
    Carosi, G
    Dhumeaux, D
    Craxì, A
    Chaneac, M
    Reddy, KR
    JOURNAL OF HEPATOLOGY, 2005, 43 (03) : 425 - 433
  • [37] Modeling the impact of peginterferon alfa-2a (40KD) (Pegasys®) plus ribavirin therapy on life expectancy and medical care costs in chronic hepatitis C.
    Jensen, CDM
    Bernstein, DE
    Hassanein, TI
    Foster, GR
    Lee, SS
    Cheinquer, H
    Craxi, A
    Cooksley, WGE
    Klaskala, W
    Green, J
    HEPATOLOGY, 2002, 36 (04) : 603A - 603A
  • [38] Efficacy and safety of peginterferon alfa-2a (40KD) (PEGASYS®) in patients with chronic hepatitis B who had received prior treatment with nucleos(t)ide analogues -: the PEGaLAM cohort
    Piratvisuth, Teerha
    Boyer, Nathalie
    Tanwandee, Tawesak
    Huat, Robert Pooi
    Gadano, Adrian
    Mercado, Randy
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2006, 21 : A32 - A32
  • [39] A dynamic model to predict sustained virological response to combination peginterferon alfa-2a (40KD) (PEGASYS®) and ribavirin (COPEGUS®) therapy in patients with chronic hepatitis C.
    Ferenci, P
    Fried, MW
    Chaneac, M
    HEPATOLOGY, 2003, 38 (04) : 635A - 635A
  • [40] Peginterferon alfa-2a (40kd) (Pegasys®) plus ribavirin in chronic hepatitis C:: Retreatment of patients who relapsed virologically after 24 weeks of therapy.
    Goncales, F
    Bernstein, DE
    Berg, C
    Sette, H
    Rasenack, J
    Diago, M
    Jensen, DM
    Cooksley, WGE
    Roberts, P
    Ackrill, AM
    HEPATOLOGY, 2002, 36 (04) : 361A - 361A
12345